RÉSUMÉ
OBJECTIVE: This study was to investigate the role of serum Klotho, fetuin-A, and Matrix Gla Protein (MGP) in Coronary Artery Calcification (CAC) in patients with Maintenance Hemodialysis (MHD) and their predictive value for CAC. METHODS: 100 patients receiving MHD were selected. Serum Klotho, fetuin-A, and MGP levels were detected by ELISA. CAC scores were assessed by coronary CT scan. Multifactor analysis was used to evaluate the risk factors affecting CAC. The ability of serum Klotho, fetuin-A, and MGP levels to diagnose CAC was evaluated by receiver operating characteristic curves. RESULTS: Serum Klotho, fetuin-A, and MGP were independent risk factors for CAC. Serum Klotho, fetuin-A, and MGP were valuable in the diagnosis of CAC in MHD patients. CONCLUSION: There is a close relationship between Klotho, fetuin-A, and MGP levels in MHD patients and CAC.
Sujet(s)
Marqueurs biologiques , Protéines de liaison au calcium , Maladie des artères coronaires , Protéines de la matrice extracellulaire , Glucuronidase , Protéines Klotho , , Dialyse rénale , Calcification vasculaire , alpha-2-HS-glycoprotéine , Humains , Dialyse rénale/effets indésirables , Mâle , Femelle , Protéines de liaison au calcium/sang , Adulte d'âge moyen , alpha-2-HS-glycoprotéine/analyse , alpha-2-HS-glycoprotéine/métabolisme , Maladie des artères coronaires/sang , Maladie des artères coronaires/imagerie diagnostique , Glucuronidase/sang , Protéines de la matrice extracellulaire/sang , Marqueurs biologiques/sang , Calcification vasculaire/sang , Calcification vasculaire/imagerie diagnostique , Sujet âgé , Facteurs de risque , Test ELISA , Adulte , Courbe ROC , Calcinose/sang , Calcinose/imagerie diagnostique , Calcinose/étiologie , Valeur prédictive des testsRÉSUMÉ
BACKGROUND: Patients with atrial fibrillation (AF) often have coronary artery disease (CAD), but the biological link between them remains unclear. This study aims to explore the common pathogenesis of AF and CAD and identify common biomarkers. METHODS: Gene expression profiles for AF and stable CAD were downloaded from the Gene Expression Omnibus database. Overlapping genes related to both diseases were identified using weighted gene co-expression network analysis (WGCNA), followed by functional enrichment analysis. Hub genes were then identified using the machine learning algorithm. Immune cell infiltration and correlations with hub genes were explored, followed by drug predictions. Hub gene expression in AF and CAD patients was validated by real-time qPCR. RESULTS: We obtained 28 common overlapping genes in AF and stable CAD, mainly enriched in the PI3K-Akt, ECM-receptor interaction, and relaxin signaling pathway. Two hub genes, COL6A3 and FKBP10, were positively correlated with the abundance of MDSC, plasmacytoid dendritic cells, and regulatory T cells in AF and negatively correlated with the abundance of CD56dim natural killer cells in CAD. The AUCs of COL6A3 and FKBP10 were all above or close to 0.7. Drug prediction suggested that collagenase clostridium histolyticum and ocriplasmin, which target COL6A3, may be potential drugs for AF and stable CAD. Additionally, COL6A3 and FKBP10 were upregulated in patients with AF and CAD. CONCLUSION: COL6A3 and FKBP10 may be key biomarkers for AF and CAD, providing new insights into the diagnosis and treatment of this disease.
Sujet(s)
Fibrillation auriculaire , Maladie des artères coronaires , Bases de données génétiques , Analyse de profil d'expression de gènes , Réseaux de régulation génique , Apprentissage machine , Transcriptome , Humains , Fibrillation auriculaire/génétique , Fibrillation auriculaire/diagnostic , Maladie des artères coronaires/génétique , Maladie des artères coronaires/diagnostic , Maladie des artères coronaires/immunologie , Valeur prédictive des tests , Marqueurs génétiques , Marqueurs biologiques/sang , Mâle , FemelleRÉSUMÉ
ABSTRACT: The dual pathway inhibition (DPI) with low-dose rivaroxaban and aspirin in patients with stable atherosclerotic vascular disease reduces the occurrence of cardiovascular events, with no significant increase of intracranial or other critical organ bleedings. Our observational study aimed to describe the clinical performance, adherence, and persistence of DPI therapy among a real-world setting of patients with an established diagnosis of coronary artery (CAD) and/or peripheral artery disease (PAD). We prospectively included all consecutive patients with an established diagnosis of CAD and/or PAD treated with aspirin (ASA) 100 mg once daily and rivaroxaban 2.5 mg twice daily. Clinical evaluation was performed at baseline, before starting treatment, at 1 month, and every 6 months after the study drug administration. A total of 202 consecutive patients (mean age 66 ± 10 years; male 80%) eligible to DPI therapy were included. During a mean follow-up of 664 ± 177 days, the incidence rate of major bleedings and of major adverse cardiovascular events was 0.8 and 1.1 per 100 patients/year, respectively. The adherence to pharmacological treatment was 99%. Additionally, 13.4% of patients suspended the DPI therapy during the follow-up. Minor bleedings resulted the most common cause of both temporary and permanent DPI therapy discontinuation. This observational study supports the safety of DPI with low-dose rivaroxaban and aspirin among patients with CAD and PAD in a real-world setting, showing high persistence and maximum adherence to medical treatment.
Sujet(s)
Acide acétylsalicylique , Maladie des artères coronaires , Inhibiteurs du facteur Xa , Hémorragie , Adhésion au traitement médicamenteux , Maladie artérielle périphérique , Antiagrégants plaquettaires , Rivaroxaban , Humains , Rivaroxaban/effets indésirables , Rivaroxaban/administration et posologie , Acide acétylsalicylique/effets indésirables , Acide acétylsalicylique/administration et posologie , Acide acétylsalicylique/usage thérapeutique , Mâle , Sujet âgé , Femelle , Inhibiteurs du facteur Xa/effets indésirables , Inhibiteurs du facteur Xa/administration et posologie , Maladie artérielle périphérique/traitement médicamenteux , Maladie artérielle périphérique/diagnostic , Maladie artérielle périphérique/physiopathologie , Maladie artérielle périphérique/épidémiologie , Études prospectives , Adulte d'âge moyen , Hémorragie/induit chimiquement , Résultat thérapeutique , Antiagrégants plaquettaires/effets indésirables , Antiagrégants plaquettaires/administration et posologie , Antiagrégants plaquettaires/usage thérapeutique , Facteurs temps , Maladie des artères coronaires/traitement médicamenteux , Maladie des artères coronaires/diagnostic , Facteurs de risqueRÉSUMÉ
BACKGROUND: Observational studies have reported associations between primary aldosteronism (PA) and cardiovascular outcomes, including coronary artery diseases (CAD), congestive heart failure (CHF), and stroke. However, establishing causality remains a challenge due to the lack of randomized controlled trial data on this topic. We thus aimed to investigate the causal relationship between PA and the risk of developing CAD, CHF, and stroke. METHODS AND RESULTS: Cross-ancestry meta-analysis of genome-wide association studies combining East Asian and European ancestry (1560 PA cases and 742 139 controls) was conducted to identify single-nucleotide variants that are associated with PA. Then, using the identified genetic variants as instrumental variables, we conducted the 2-sample Mendelian randomization analysis to investigate the causal relationship between PA and incident CAD, CHF, and stroke among both East Asian and European ancestry. Summary association results were extracted from large genome-wide association studies consortia. Our cross-ancestry meta-analysis of East Asian and European populations identified 7 genetic loci significantly associated with the risk of PA, for which the genes nearest to the lead variants were CASZ1, WNT2B, HOTTIP, LSP1, TBX3, RXFP2, and NDP. Among the East Asian population, the pooled odds ratio estimates using these 7 genetic instruments of PA were 1.07 (95% CI, 1.03-1.11) for CAD, 1.10 (95% CI, 1.01-1.20) for CHF, and 1.13 (95% CI, 1.09-1.18) for stroke. The results were consistent among the European population. CONCLUSIONS: Our 2-sample Mendelian randomization study revealed that PA had increased risks of CAD, CHF, and stroke. These findings highlight that early and active screening of PA is critical to prevent future cardiovascular events.
Sujet(s)
Étude d'association pangénomique , Hyperaldostéronisme , Analyse de randomisation mendélienne , Polymorphisme de nucléotide simple , Humains , Hyperaldostéronisme/génétique , Hyperaldostéronisme/épidémiologie , Maladie des artères coronaires/génétique , Maladie des artères coronaires/épidémiologie , Prédisposition génétique à une maladie , Accident vasculaire cérébral/génétique , Accident vasculaire cérébral/épidémiologie , Asiatiques/génétique , Défaillance cardiaque/génétique , Défaillance cardiaque/épidémiologie , Défaillance cardiaque/ethnologie , /génétique , Appréciation des risques , Facteurs de risqueRÉSUMÉ
BACKGROUND: Kawasaki Disease (KD) involves arterial inflammation, primarily affecting the coronary arteries and leading to coronary artery lesions. Recent advancements in understanding the immunomodulatory roles of vitamin D have prompted investigations into the potential correlation between serum vitamin D levels and the risk of coronary artery lesions (CAL) in KD. This review aims to explore this association. METHODS: A systematic search utilizing relevant keywords related to Kawasaki disease and coronary artery lesions was conducted across four databases (PubMed, Embase, Scopus, and Web of Science). The quality of the incorporated studies was assessed utilizing the Newcastle-Ottawa Scale. The study protocol is registered in PROSPERO under the registry code CRD42024493204. RESULTS: In a review of five studies involving 442 KD patients and 594 healthy controls, KD patients generally had lower serum vitamin D levels compared to controls, with mixed findings on the association with coronary artery lesions and IVIG resistance. While three studies supported lower vitamin D in KD, one showed no significant difference. Regarding CAL, one study found lower vitamin D, another found higher levels associated with CAL, and two found no significant difference. CONCLUSIONS: Overall, the evidence is inconclusive, but there's a trend suggesting potential benefits of sufficient vitamin D levels in Kawasaki disease rather than evidence refuting any association with clinical outcomes.
Sujet(s)
Maladie des artères coronaires , Maladie de Kawasaki , Vitamine D , Maladie de Kawasaki/sang , Maladie de Kawasaki/complications , Humains , Vitamine D/sang , Maladie des artères coronaires/étiologie , Maladie des artères coronaires/sangRÉSUMÉ
BACKGROUND: Guidelines recommend the use of risk scores to select patients for further investigation after myocardial infarction has been ruled out but their utility to identify those with coronary artery disease is uncertain. METHODS: In a prospective cohort study, patients with intermediate high-sensitivity cardiac troponin I concentrations (5 ng/L to sex-specific 99th percentile) in whom myocardial infarction was ruled out were enrolled and underwent coronary CT angiography (CCTA) after hospital discharge. History, ECG, Age, Risk factors, Troponin (HEART), Emergency Department Assessment of Chest Pain Score (EDACS), Global Registry of Acute Coronary Event (GRACE), Thrombolysis In Myocardial Infarction (TIMI), Systematic COronary Risk Evaluation 2 and Pooled Cohort Equation risk scores were calculated and the odds ratio (OR) and diagnostic performance for obstructive coronary artery disease were determined using established thresholds. RESULTS: Of 167 patients enrolled (64±12 years, 28% female), 29.9% (50/167) had obstructive coronary artery disease. The odds of having obstructive disease were increased for all scores with the lowest and highest increase observed for an EDACS score ≥16 (OR 2.2 (1.1-4.6)) and a TIMI risk score ≥1 (OR 12.9 (3.0-56.0)), respectively. The positive predictive value (PPV) was low for all scores but was highest for a GRACE score >88 identifying 39% as high risk with a PPV of 41.9% (30.4-54.2%). The negative predictive value (NPV) varied from 77.3% to 95.2% but was highest for a TIMI score of 0 identifying 26% as low risk with an NPV of 95.2% (87.2-100%). CONCLUSIONS: In patients with intermediate cardiac troponin concentrations in whom myocardial infarction has been excluded, clinical risk scores can help identify patients with and without coronary artery disease, although the performance of established risk thresholds is suboptimal for utilisation in clinical practice. TRIAL REGISTRATION NUMBER: NCT04549805.
Sujet(s)
Syndrome coronarien aigu , Marqueurs biologiques , Coronarographie , Maladie des artères coronaires , Troponine I , Humains , Femelle , Mâle , Adulte d'âge moyen , Études prospectives , Appréciation des risques/méthodes , Marqueurs biologiques/sang , Maladie des artères coronaires/sang , Maladie des artères coronaires/diagnostic , Maladie des artères coronaires/épidémiologie , Syndrome coronarien aigu/sang , Syndrome coronarien aigu/diagnostic , Syndrome coronarien aigu/épidémiologie , Sujet âgé , Troponine I/sang , Facteurs de risque , Angiographie par tomodensitométrie , Valeur prédictive des tests , PronosticRÉSUMÉ
The objective of the present investigation was to compare the coronary angiography results in diabetic patients with and without end-stage kidney disease (ESKD). We included prolonged diabetic patients with ESKD (93 patients) and without ESKD (control group, 126 patients). Angiography of the coronary arteries was performed on all patients. Our results revealed that the ESKD patients tended to have a higher degree of coronary artery stenosis in all parts of LAD (p = 0.001, 0.024, and 0.005), proximal and distal RCA (p = 0.013, and 0.008), and proximal and distal LCX artery (p = 0.001, 0.008) than non-ESKD patients. Furthermore, we found that the ESKD group had higher significant coronary artery stenosis in the LAD artery (60.5% vs. 39.5%, p < 0.001), RCA (60.3% vs. 39.7%, p < 0.001), LCX artery (79.5% vs. 20.5%, p < 0.001), and LMCA (84.6% vs 15.4%, p = 0.002) compared to control group. There was a greater prevalence of multiple vessels coronary artery disease (≥ two) among ESKD patients (29%), compared with the non-ESKD group (16.8%, p < 0.001). Significant coronary artery stenosis was meaningfully higher in asymptomatic diabetic ESKD patients on hemodialysis than non-ESKD diabetic patients. Coronary angiography may be beneficial in diabetic patients with ESKD regardless of whether they have ischemic symptoms with low complication rate through radial access.
Sujet(s)
Coronarographie , Maladie des artères coronaires , Défaillance rénale chronique , Humains , Mâle , Femelle , Défaillance rénale chronique/imagerie diagnostique , Défaillance rénale chronique/complications , Défaillance rénale chronique/épidémiologie , Adulte d'âge moyen , Coronarographie/méthodes , Maladie des artères coronaires/imagerie diagnostique , Maladie des artères coronaires/épidémiologie , Sujet âgé , Sténose coronarienne/imagerie diagnostiqueRÉSUMÉ
AIM: To evaluate the prognostic value of GDF-15 in relation the development of bleeding and events in stable CAD patients, receiving combined antithrombotic therapy. MATERIALS AND METHODS: The data was obtained from the prospective registry REGATA, 343 CAD patients (249 males), median age 68 [IQR 62; 75] years) were enrolled. Patients with sinus rhythm and concomitant PAD received acetylsalicylic acid in combination with rivaroxaban 2.5 mg bid (31.8%) or clopidogrel (24.8%). Other 43.4% with concomitant atrial fibrillation (AF) received direct oral anticoagulants in combination with antiplatelet therapy after elective percutaneous coronary interventions. Median follow-up was 12 months [IQR 9.0; 18.0]. The safety end point was major and clinically relevant bleedings (type 2-5) according to the BARC classification. Plasma samples for GDF-15 identification were taken at the inclusion and analyzed using ELISA assay. RESULTS: Frequency of BARC 2-5 bleedings was 16% (BARC 2 - 46; BARC 3 - 9; BARC 4-5 - 0), median GDF-15 level was 1185.0 pg/ml [850.0; 1680.0]. In patients with AF and concomitant MFA, the level of GDF-15 was significantly higher than in the subgroups of patients with only AF or MFA (p=0.0022). According to the quintile analysis, GDF-15 values in the top three quintiles of distribution (cut-off value >943 pg/ml) were associated with higher frequency of bleeding events: 23.2% versus 5.1%; p=0.0001. The multivariable logistic regression model demonstrated that bleeding events were independently associated with GDF-15 level>943 pg/ml (OR 2.65, 95% CI 1.11-6.30; p=0.0275), AF (OR 2.61, 95% CI 1.41-4.83; p=0.0023) and chronic kidney disease (OR 1.92, 95% CI 1.03-3.60; p=0.0401). Clinical factors determining the risk of bleeding events also determined a GDF-15 elevation. CONCLUSION: Assessment of GDF-15 level may improve bleeding risk stratification in CAD patients with concomitant AF and/or PAD receiving combined antithrombotic therapy.
Sujet(s)
Facteur-15 de croissance et de différenciation , Hémorragie , Enregistrements , Humains , Mâle , Femelle , Sujet âgé , Hémorragie/induit chimiquement , Hémorragie/épidémiologie , Hémorragie/étiologie , Adulte d'âge moyen , Facteur-15 de croissance et de différenciation/sang , Études prospectives , Maladie des artères coronaires/complications , Maladie des artères coronaires/sang , Association de médicaments , Fibrillation auriculaire/traitement médicamenteux , Fibrillation auriculaire/complications , Fibrinolytiques/administration et posologie , Fibrinolytiques/effets indésirables , Acide acétylsalicylique/administration et posologie , Acide acétylsalicylique/effets indésirables , Clopidogrel/administration et posologie , Clopidogrel/effets indésirables , Pronostic , Russie/épidémiologie , Antiagrégants plaquettaires/administration et posologie , Antiagrégants plaquettaires/effets indésirables , Rivaroxaban/administration et posologie , Rivaroxaban/effets indésirables , Intervention coronarienne percutanée/méthodes , Intervention coronarienne percutanée/effets indésirablesRÉSUMÉ
BACKGROUND: Premature coronary artery disease (PCAD) is prevailing. We aimed to investigate the evaluation value of atherogenic index of plasma (AIP) and high-sensitivity C-reactive protein (hs-CRP) for the occurrence and severity of coronary artery lesion in PCAD patients. METHODS: PCAD (PACD group)/non-PCAD (control group) patients were enrolled. The coronary artery lesion degree was evaluated using Gensini score (GS). PCAD patients were allocated into the low/medium/high GS groups, with general clinical baseline data analyzed. Plasma hs-CRP/AIP levels were compared in PCAD patients with different disease degree. Correlations between plasma hs-CRP/AIP with Gensini score, independent risk factors affecting the occurrence of PCAD, and the predictive value of hs-CRP/AIP/their combination for the occurrence and degree of PCAD were evaluated by Spearman correlation analysis/Logistic multivariate regression/receiver operating characteristic (ROC) curve. The differences in the area under the curve (AUC) were compared using MedCalc-Comparison of ROC curves. RESULTS: Plasma hs-CRP/AIP levels in the PCAD group were increased. Plasma hs-CRP/AIP levels varied significantly among PCAD patients with different disease degree. Plasma hs-CRP/AIP levels were markedly positively correlated with the Gensini score. Smoking history/homocysteine/fasting blood-glucose/hs-CRP/AIP were all independent risk factors affecting PCAD occurrence. The AUC of hs-CRP and AIP combination predicting the occurrence of PCAD was 0.950 (90.80% sensitivity/93.33% specificity). hs-CRP/AIP combination assisted in predicting the disease degree in PCAD patients. CONCLUSIONS: AIP and hs-CRP are independent risk factors for the occurrence of PCAD, and their combination has high predictive value for PCAD occurrence and disease degree, which are both positively correlated with coronary artery lesion degree.
Sujet(s)
Marqueurs biologiques , Protéine C-réactive , Maladie des artères coronaires , Valeur prédictive des tests , Indice de gravité de la maladie , Humains , Maladie des artères coronaires/sang , Maladie des artères coronaires/diagnostic , Maladie des artères coronaires/imagerie diagnostique , Protéine C-réactive/analyse , Mâle , Femelle , Adulte d'âge moyen , Marqueurs biologiques/sang , Adulte , Études cas-témoins , Appréciation des risques , Facteurs de risque , Coronarographie , PronosticRÉSUMÉ
OBJECTIVE: Coronary artery ectasia (CAE) is a condition characterized by the localized or widespread dilation of one or more coronary arteries. The majority of CAE patients do not present with clinical symptoms, and the exact cause of CAE remains unclear. Therefore, a retrospective analysis was conducted to explore the potential causes of CAE. METHODS: This study was a retrospective analysis of patients who underwent coronary angiography at Guangdong Provincial People's Hospital between January 2017 and July 2022, of whom 679 patients were ultimately enrolled in the study. Among them, 260 patients were diagnosed with CAE, whereas 419 patients with normal coronary results composed the control group. Remnant cholesterol (RC) was calculated as total cholesterol (TC) minus high-density lipoprotein cholesterol (HDL-C) minus low-density lipoprotein cholesterol (LDL-C). The association between RC levels and the risk of CAE was assessed via multivariable logistic models. RESULTS: Out of the 679 patients who participated in this study, with an average age of 59.9 years, 38.3% were diagnosed with CAE. Patients with CAE had higher RC levels than did those without CAE (P = 0.001). A significant positive association was observed between RC levels and the risk of CAE, with a multivariable adjusted odds ratio (OR) of 1.950 (95% confidence interval [CI]: 1.163-3.270). There was a significant positive association between RC levels and the risk of CAE in both single-vessel and multivessel dilation cases, as well as in isolated CAE and dilation secondary to coronary atherosclerosis. According to the subgroup analyses, RC levels were positively associated with the risk of CAE in participants with hypertension (OR, 1.065; 95% CI, 1.034-1.098). CONCLUSION: RC levels are positively correlated with CAE, implying that a focus on RC could be beneficial in CAE research.
Sujet(s)
Cholestérol HDL , Cholestérol LDL , Cholestérol , Coronarographie , Maladie des artères coronaires , Vaisseaux coronaires , Humains , Adulte d'âge moyen , Mâle , Femelle , Études transversales , Cholestérol/sang , Dilatation pathologique/sang , Études rétrospectives , Maladie des artères coronaires/sang , Maladie des artères coronaires/anatomopathologie , Maladie des artères coronaires/imagerie diagnostique , Sujet âgé , Cholestérol LDL/sang , Vaisseaux coronaires/anatomopathologie , Vaisseaux coronaires/imagerie diagnostique , Cholestérol HDL/sang , Facteurs de risque , Triglycéride/sang , Odds ratioSujet(s)
Maladie des artères coronaires , Intervention coronarienne percutanée , Humains , Maladie des artères coronaires/thérapie , Maladie des artères coronaires/imagerie diagnostique , Résultat thérapeutique , Intervention coronarienne percutanée/effets indésirables , Intervention coronarienne percutanée/instrumentation , EndoprothèsesRÉSUMÉ
Coronary intervention involving the region of bifurcation remains a challenging issue for the cardiologist as well as a complication. A number of factors including the angulation of side branch with the main branch determines the success. Though provisional strategy remains the best option in bifurcation intervention, at times a two-stent strategy cannot be avoided. We report a case in which percutaneous coronary intervention was performed on the left anterior descending artery (LAD) at its bifurcation with a major diagonal branch (> 2.5 mm). The ostium of the diagonal was diseased, and the branch took off from the LAD at an unfavorable angle (> 120°). We describe the use of the "shepherd's crook wire curve" approach, a modification of the reverse wire technique, which allowed us to successfully wire, dilate, and protect the diagonal and so named to reflect its resemblance to the shape of a shepherd's crook.
Sujet(s)
Angioplastie coronaire par ballonnet , Coronarographie , Maladie des artères coronaires , Humains , Résultat thérapeutique , Maladie des artères coronaires/imagerie diagnostique , Maladie des artères coronaires/thérapie , Maladie des artères coronaires/chirurgie , Angioplastie coronaire par ballonnet/instrumentation , Mâle , Endoprothèses à élution de substances , Sondes cardiaques , Sujet âgéRÉSUMÉ
BACKGROUND: We aimed to find a gene for coronary artery disease (CAD) early diagnosis by detecting co-pathogenic target gene involved in CAD and pulmonary arterial hypertension (PAH). Methods: Datasets were obtained from the Gene Expression Omnibus (GEO) database, including GSE113079, GSE113439, and GSE12288, to investigate gene expression patterns in cardiovascular diseases. Weighted Gene Co-expression Network Analysis (WGCNA) was performed to identify gene modules associated with clinical traits. Differential gene expression analysis and functional enrichment analysis were carried out. Protein-protein interaction (PPI) networks were constructed. JASPAR database and FIMO tool were utilized to predict transcription factor (TF) binding sites. Results: Fifteen key genes were identified in CAD and PAH, with CNTN1 being prioritized for further investigation due to its high connectivity degree. Upstream regulation analysis identified potential TFs (DRGX, HOXD3, and RAX) and 7 miRNAs targeting CNTN1. The expression profile of CNTN1 was significantly upregulated in CAD samples, and ROC analysis indicated potential diagnostic value for CAD. CMap database analysis predicted potential targeted drugs for CAD. Conclusion: CNTN1 was detected as a co-pathogenetic gene for CAD and PAH. It is highly expressed in CAD patients and has potential value for CAD diagnosis. CNTN1 is potentially regulated by 3 TFs and 7 miRNAs.
Sujet(s)
Maladie des artères coronaires , Humains , Maladie des artères coronaires/génétique , Maladie des artères coronaires/diagnostic , Hypertension artérielle pulmonaire/génétique , Hypertension artérielle pulmonaire/diagnosticRÉSUMÉ
Coronary artery disease (CAD) is the leading cause of death in India. Many genetic polymorphisms play a role in regulating oxidative stress, blood pressure and lipid metabolism, contributing to the pathophysiology of CAD. This study examined the association between ten polymorphisms and CAD in the Jat Sikh population from Northern India, also considering polygenic risk scores. This study included 177 CAD cases and 175 healthy controls. The genetic information of GSTM1 (rs366631), GSTT1 (rs17856199), ACE (rs4646994), AGT M235T (rs699), AGT T174M (rs4762), AGTR1 A1166C (rs5186), APOA5 (rs3135506), APOC3 (rs5128), APOE (rs7412) and APOE (rs429358) and clinical information was collated. Statistical analyses were performed using SPSS version 27.0 and SNPstats. Significant independent associations were found for GST*M1, GST*T1, ACE, AGT M235T, AGT T174M, AGTR1 A1166C and APOA5 polymorphisms and CAD risk (all p < 0.05). The AGT CT haplotype was significantly associated with a higher CAD risk, even after controlling for covariates (adjusted OR = 3.93, 95% CI [2.39-6.48], p < 0.0001). The APOA5/C3 CC haplotype was also significantly associated with CAD (adjusted OR = 1.86, 95% CI [1.14-3.03], p < 0.05). A higher polygenic risk score was associated with increased CAD risk (adjusted OR = 1.98, 95% CI [1.68-2.34], p < 0.001). Seven polymorphisms were independently associated with an increase in the risk of CAD in this North Indian population. A considerable risk association of AGT, APOA5/C3 haplotypes and higher genetic risk scores is documented, which may have implications for clinical and public health applications.
Sujet(s)
Angiotensinogène , Apolipoprotéine A-V , Apolipoprotéines E , Maladie des artères coronaires , , Glutathione transferase , Polymorphisme de nucléotide simple , Sujet âgé , Femelle , Humains , Mâle , Adulte d'âge moyen , Angiotensinogène/génétique , Apolipoprotéine A-V/génétique , Apolipoprotéine C-III , Apolipoprotéines E/génétique , Études cas-témoins , Maladie des artères coronaires/génétique , Maladie des artères coronaires/épidémiologie , Fréquence d'allèle , Études d'associations génétiques , Glutathione transferase/génétique , Haplotypes , Inde/épidémiologie , Peptidyl-Dipeptidase A/génétique , Récepteur de type 1 à l'angiotensine-II/génétique , Facteurs de risqueRÉSUMÉ
BACKGROUND: Stent malapposition (SM) following percutaneous coronary intervention (PCI) for myocardial infarction continues to present significant clinical challenges. In recent years, machine learning (ML) models have demonstrated potential in disease risk stratification and predictive modeling. HYPOTHESIS: ML models based on optical coherence tomography (OCT) imaging, laboratory tests, and clinical characteristics can predict the occurrence of SM. METHODS: We studied 337 patients from the Affiliated Hospital of Zunyi Medical University, China, who had PCI and coronary OCT from May to October 2023. We employed nested cross-validation to partition patients into training and test sets. We developed five ML models: XGBoost, LR, RF, SVM, and NB based on calcification features. Performance was assessed using ROC curves. Lasso regression selected features from 46 clinical and 21 OCT imaging features, which were optimized with the five ML algorithms. RESULTS: In the prediction model based on calcification features, the XGBoost model and SVM model exhibited higher AUC values. Lasso regression identified five key features from clinical and imaging data. After incorporating selected features into the model for optimization, the AUC values of all algorithmic models showed significant improvements. The XGBoost model demonstrated the highest calibration accuracy. SHAP values revealed that the top five ranked features influencing the XGBoost model were calcification length, age, coronary dissection, lipid angle, and troponin. CONCLUSION: ML models developed using plaque imaging features and clinical characteristics can predict the occurrence of SM. ML models based on clinical and imaging features exhibited better performance.
Sujet(s)
Maladie des artères coronaires , Apprentissage machine , Intervention coronarienne percutanée , Plaque d'athérosclérose , Tomographie par cohérence optique , Humains , Études rétrospectives , Mâle , Tomographie par cohérence optique/méthodes , Femelle , Adulte d'âge moyen , Intervention coronarienne percutanée/instrumentation , Intervention coronarienne percutanée/méthodes , Maladie des artères coronaires/diagnostic , Maladie des artères coronaires/chirurgie , Chine/épidémiologie , Vaisseaux coronaires/imagerie diagnostique , Vaisseaux coronaires/anatomopathologie , Sujet âgé , Endoprothèses , Infarctus du myocarde/diagnostic , Valeur prédictive des tests , Facteurs de risque , Appréciation des risques/méthodes , CoronarographieSujet(s)
Maladie des artères coronaires , Intervention coronarienne percutanée , Humains , Maladie des artères coronaires/thérapie , Maladie des artères coronaires/imagerie diagnostique , Intervention coronarienne percutanée/effets indésirables , Intervention coronarienne percutanée/instrumentation , Résultat thérapeutiqueRÉSUMÉ
OBJECTIVE: To explore trends in prognosis and use of glucose-lowering drugs (GLD) in patients with diabetes and coronary artery disease (CAD). RESEARCH DESIGN AND METHODS: All patients with diabetes and CAD undergoing a coronary angiography between 2010 and 2021 according to the Swedish Angiography and Angioplasty Registry were included. Information on GLD (dispended 6 months before or after coronary angiography) was collected from the Swedish Prescribed Drug Registry. Data on major cardiovascular events (MACE; mortality, myocardial infarction, stroke, heart failure) through December 2021 were obtained from national registries. Cox proportional survival analysis was used to assess outcomes where cardioprotective GLD (any of Sodium Glucose Lowering Transport 2 receptor inhibitors [SGLT2i] and Glucagon Like Peptide Receptor Agonists [GLP-1 RA]) served as a reference. RESULTS: Among all patients (n = 38,671), 31% had stable CAD, and 69% suffered an acute myocardial infarction. Mean age was 69 years, 67% were male, and 81% were on GLD. The use of cardioprotective GLD increased rapidly in recent years (2016-2021; 7-47%) and was more common in younger patients (66 vs. 68 years) and men (72.9% vs. 67.1%) than other GLD. Furthermore, compared with other GLD, the use of cardioprotective GLD was more common in patients with a less frequent history of heart failure (5.0% vs. 6.8%), myocardial infarction (7.7% vs. 10.5%) and chronic kidney disease (3.7% vs. 5.2%). The adjusted hazard ratio (HR) (95% CI) for MACE was greater in patients on other GLD than in those on cardioprotective GLD (1.10; 1.03-1.17, p = 0.004). Trend analyses for the years 2010-2019 revealed improved one-year MACE in patients with diabetes and CAD (year 2019 vs. 2010; 0.90; 0.81-1.00, p = 0.045), while 1-year mortality was unchanged. CONCLUSIONS: The prescription pattern of diabetes medication is changing quickly in patients with diabetes and CAD; however, there are worrying signals of inefficient use prioritizing cardioprotective GLD to younger and healthier individuals at lower cardiovascular risk. Despite this, there are improving trends in 1-year morbidity.
Sujet(s)
Maladie des artères coronaires , Récepteur du peptide-1 similaire au glucagon , Enregistrements , Inhibiteurs du cotransporteur sodium-glucose de type 2 , Humains , Mâle , Femelle , Sujet âgé , Suède/épidémiologie , Maladie des artères coronaires/mortalité , Maladie des artères coronaires/diagnostic , Maladie des artères coronaires/épidémiologie , Maladie des artères coronaires/imagerie diagnostique , Maladie des artères coronaires/traitement médicamenteux , Adulte d'âge moyen , Facteurs temps , Récepteur du peptide-1 similaire au glucagon/agonistes , Appréciation des risques , Résultat thérapeutique , Inhibiteurs du cotransporteur sodium-glucose de type 2/usage thérapeutique , Inhibiteurs du cotransporteur sodium-glucose de type 2/effets indésirables , Facteurs de risque , Incrétines/usage thérapeutique , Incrétines/effets indésirables , Types de pratiques des médecins/tendances , Diabète de type 2/traitement médicamenteux , Diabète de type 2/mortalité , Diabète de type 2/diagnostic , Diabète de type 2/épidémiologie , Coronarographie/tendances , Sujet âgé de 80 ans ou plus , Glycémie/métabolisme , Glycémie/effets des médicaments et des substances chimiquesRÉSUMÉ
BACKGROUND: The impact of rosuvastatin versus atorvastatin on new-onset diabetes mellitus (NODM) among patients treated with high-intensity statin therapy for coronary artery disease (CAD) remains to be clarified. This study aimed to evaluate the risk of NODM in patients with CAD treated with rosuvastatin compared to atorvastatin in the randomized LODESTAR trial. METHODS: In the LODESTAR trial, patients with CAD were randomly assigned to receive either rosuvastatin or atorvastatin using a 2-by-2 factorial randomization. In this post-hoc analysis, the 3-year incidence of NODM was compared between rosuvastatin and atorvastatin treatment in the as-treated population with high-intensity statin therapy as the principal population of interest. RESULTS: Among 2932 patients without diabetes mellitus at baseline, 2377 were included in the as-treated population analysis. In the as-treated population with high-intensity statin therapy, the incidence of NODM was not significantly different between the rosuvastatin and atorvastatin groups (11.4% [106/948] versus 8.8% [73/856], hazard ratio [HR] = 1.32, 95% confidence interval [CI] = 0.98 to 1.77, P = 0.071). When the risk of NODM with rosuvastatin versus atorvastatin was assessed according to the achieved low-density lipoprotein cholesterol (LDL-C) level, the risk of NODM began to increase at a LDL-C level below 70 mg/dL. The incidence of NODM was significantly greater in the rosuvastatin group than it was in the atorvastatin group when the achieved LDL-C level was < 70 mg/dL (13.9% versus 8.0%; HR = 1.79, 95% CI 1.18 to 2.73, P = 0.007). CONCLUSIONS: Among CAD patients receiving high-intensity statin therapy, the incidence of NODM was not significantly different between rosuvastatin and atorvastatin. However, a drug effect of the statin type on NODM was observed when the achieved LDL-C level was < 70 mg/dL. TRIAL REGISTRATION: ClinicalTrials.gov, Identifier: NCT02579499.
Sujet(s)
Atorvastatine , Maladie des artères coronaires , Diabète , Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase , Rosuvastatine de calcium , Humains , Rosuvastatine de calcium/effets indésirables , Rosuvastatine de calcium/usage thérapeutique , Atorvastatine/effets indésirables , Atorvastatine/usage thérapeutique , Maladie des artères coronaires/épidémiologie , Maladie des artères coronaires/sang , Maladie des artères coronaires/diagnostic , Maladie des artères coronaires/traitement médicamenteux , Mâle , Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase/effets indésirables , Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase/usage thérapeutique , Femelle , Adulte d'âge moyen , Sujet âgé , Diabète/diagnostic , Diabète/épidémiologie , Diabète/sang , Diabète/traitement médicamenteux , Incidence , Résultat thérapeutique , Facteurs de risque , Facteurs temps , Marqueurs biologiques/sang , Appréciation des risquesRÉSUMÉ
Background: Glycosylated hemoglobin (HbA1c) variability is a risk factor for cardiovascular complications in patients with Type 2 diabetes mellitus (T2DM), but its relationship with the severity of coronary artery disease (CAD) is unclear. Methods: Patients with T2DM who underwent coronary angiography due to angina were enrolled. HbA1c variability was expressed as coefficient of variation (CV), standard deviation (SD), variability independent of mean (VIM), and time in range (TIR). The severity of CAD was expressed by the number of involved vessels and Gensini score. Multivariate regression models were constructed to test the relationship between HbA1c variability, number of involved vessels, and the Gensini score, followed by linear regression analysis. Results: A total of 147 patients were included. In multivariate analysis, VIM-HbA1c (OR = 2.604; IQR: 1.15, 5.90; r = 0.026) and HbA1cTIR (OR = 0.13; IQR: 0.04, 0.41; r < 0.001) were independent risk factors for the number of involved vessels. After adjustment, HbA1cTIR (OR = 0.01; IQR: 0.002, 0.04; r < 0.001), SD-HbA1c (OR = 4.12, IQR: 1.64, 10.35; r = 0.001), CV-HbA1c (OR = 1.41, IQR: 1.04, 1.92; r = 0.007), and VIM-HbA1c (OR = 3.26; IQR: 1.43, 7.47; r = 0.003) were independent risk factors for the Gensini score. In the linear analysis, the Gensini score was negatively correlated with HbA1cTIR (ß = -0.629; r < 0.001) and positively correlated with SD-HbA1c (ß = 0.271; r = 0.001) and CV-HbA1c (ß = 0.176; r = 0.033). After subgroup analysis, HbA1cTIR was a risk factor for the number of involved vessels. The Gensini score was negatively correlated with HbA1cTIR and positively correlated with SD-HbA1c at subgroups of subjects with a mean HbA1c ≤ 7%. Conclusions: Our analysis indicates that HbA1c variability, especially HbA1cTIR, plays a role for the severity of CAD in patients with T2DM. HbA1c variability may provide additional information and require management even at the glycemic target. Translational Aspects: Studies have shown that HbA1c variability is related to cardiovascular complications. Further, we explore the correlation between HbA1c variability and the severity of CAD. HbA1c variability is a risk factor for coronary stenosis in T2DM. It may be a potential indicator reflecting glycemic control for the prevention and treatment of cardiovascular complications.
Sujet(s)
Coronarographie , Maladie des artères coronaires , Diabète de type 2 , Hémoglobine glyquée , Indice de gravité de la maladie , Humains , Diabète de type 2/complications , Diabète de type 2/sang , Hémoglobine glyquée/métabolisme , Hémoglobine glyquée/analyse , Mâle , Maladie des artères coronaires/sang , Maladie des artères coronaires/épidémiologie , Femelle , Adulte d'âge moyen , Sujet âgé , Facteurs de risque , Analyse multifactorielleRÉSUMÉ
Background: The debate on percutaneous coronary intervention (PCI) of the unprotected left main coronary artery (LMCA) has been constant over time. Objective: To investigate the clinical and procedural characteristics and cardiovascular outcomes of PCI of unprotected LMCA. Material and methods: Observational study which included patients with unprotected LMCA disease undergoing PCI; patients with cardiogenic shock prior to the procedure were excluded. We describe the clinical and angiographic characteristics, as well as the major adverse cardiac and cerebrovascular events (MACCE) according to the year of the procedure. Results: We included 73 patients, with a SYNTAX I score of 31.2 ± 9.1, mostly with ST-elevation acute coronary syndrome (35%). There was a higher frequency of triple vessel coronary disease (63%) and distal LMCA lesions (35%). The provisional stent technique was the most used for distal lesions (58%) and the 2-stent technique for bifurcation lesions (78%), supported by intravascular ultrasound (IVUS) in 38%. During follow-up, 19 presented MACCE (26%), out of which cardiac death occurred in 13%, non-cardiovascular death in 5%, non-fatal acute myocardial infarction in 1%, cerebrovascular event in 2%, and revascularization of the treated vessel in 4%. Conclusions: It was observed a similar frequency to the one appearing in other studies of cardiovascular events, mainly in patients with intermediate risk, which supports the increasing use of percutaneous intervention in this population.
Introducción: el debate sobre la intervención coronaria percutánea (ICP) del tronco coronario izquierdo (TCI) no protegido ha sido constante a lo largo del tiempo. Objetivo: investigar las características clínicas, de procedimiento y los desenlaces cardiovasculares de la ICP del TCI no protegido. Material y métodos: estudio observacional que incluyó pacientes con enfermedad del TCI no protegido sometidos a ICP; se excluyeron pacientes con choque cardiogénico previo al procedimiento. Describimos las características clínicas y angiográficas, así como los eventos adversos cardiovasculares y cerebrales mayores (MACCE) según el año del procedimiento. Resultados: incluimos 73 pacientes, con puntuación de SYNTAX I de 31.2 ± 9.1, mayormente con síndrome coronario agudo con elevación del ST (35%). Hubo mayor frecuencia de enfermedad coronaria trivascular (63%) y lesión distal del TCI (35%). La técnica de stent provisional fue la más usada para lesiones distales (58%) y la técnica de 2 stents para las lesiones en bifurcación (78%), con apoyo del ultrasonido intravascular (IVUS) en el 38%. En el seguimiento se presentaron 19 MACCE (26%), de los cuales la muerte de causa cardiaca se presentó en el 13%, muerte no cardiovascular en 5%, infarto agudo al miocardio no fatal en 1%, evento vascular cerebral en 2% y nueva revascularización del vaso tratado en 4%. Conclusiones: se observó una frecuencia similar a la de otros estudios de eventos cardiovasculares, especialmente en pacientes con riesgo intermedio, lo cual apoya el uso creciente de la intervención percutánea en esta población.